Pattern of HCV Genotypes in HIV/HCV Co-Infected Patients on Antiretroviral Therapy in Nigeria

Abstract

At least 33 million people worldwide are living with human immunodeficiency virus (HIV) infection, and about 20-30% of these are also infected with hepatitis C virus (HCV). Co-infection with HIV and HCV is a major public health concern. Co-infected persons develop cirrhosis and end-stage liver disease more quickly than individuals infected with HCV only. The particular HCV strain or genotype is a major factor for HCV prognosis. The pattern of HCV genotypes in a cohort of HIV/HCV co-infected patients was investigated. One hundred (100) adult patients were recruited from the Nigerian Institute of Medical Research (NIMR), Yaba, Lagos, with age ranging from 18 to 65 years (58% male). Upon recruitment, they were placed on appropriate antiretroviral drugs; 300 mg tenofovir (TDF), 200 mg emtricitabine (FTC) plus 600 mg efavirenz (EFV) once daily dosage. HCV genotyping was done using the Linear Array hepatitis C virus genotyping kit (Roche Molecular Systems, Inc. USA). HCV genotyping revealed prevalence of genotypes 1 (65.6%) and 4 (34.4%), respectively. These are the hard-to-treat genotypes that previously required a long duration of HCV therapy until newer drugs were introduced. The nature of HCV genotypes in HIV/HCV co-infected people has serious implications for further HCV therapy. These findings are pertinent for decisions about the best possible time for and kind of HCV treatment in the setting of co-morbid HIV infection.